TSERNYLTON
Active material: Graminex G60, Graminex GFX
When ATH: G04CX
CCF: Phyto, used for diseases of the prostate
ICD-10 codes (testimony): N40, N41
When CSF: 28.01.03
Manufacturer: Gramineks Pharma Group Ltd. (Russia)
Pharmaceutical form, composition and packaging
◊ Pills round, lenticular, from pale yellow to light yellow, with small patches of darker shade, engraved with the company logo on one side, and odor.
| 1 tab. | |
| Graminex G60 (water-soluble fraction of microbiologically fermented pollen extract) | 60 mg |
| Graminex GFX (fat-soluble fraction of microbiologically fermented pollen extract) | 3 mg |
Excipients: microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate.
100 PC. – vials of dark glass (1) – packs cardboard.
100 PC. – bottles of high density polyethylene (1) – packs cardboard.
200 PC. – vials of dark glass (1) – packs cardboard.
200 PC. – bottles of high density polyethylene (1) – packs cardboard.
Pharmacological action
Drug, used for diseases of the prostate. Tsernylton® anti-inflammatory and anti-edema effect, participates in the regulation of metabolic processes. One of the pharmacological properties of the active ingredients of the drug Tsernilton® a dose-dependent inhibition of COX and 5-lipoxygenase, which leads to inhibition of the synthesis of inflammatory mediators cycle arachidonic acid – prostaglandins and leukotrienes – and, Consequently, to reduce inflammation and swelling of the prostate tissue. The drug helps to eliminate pain.
Tsernylton® It has the effect of muscle relaxant, that causes relaxation of smooth muscle of the rear wall of the urethra and improve urination.
Tsernylton® It reduces the volume of the prostate by 5α-reductase inhibition, selectively blocks α1-adrenergic receptors of the smooth muscle of the urethra items, It has anti-androgenic effect. It improves erectile function.
Pharmacokinetics
The data on the pharmacokinetics Tsernilton® not provided.
Testimony
In the combined therapy:
- Acute prostatitis;
- Chronic prostatitis;
- Benign prostatic hyperplasia;
- Benign prostatic hyperplasia combined with prostatitis.
Dosage regimen
The drug is prescribed inside for 30 minutes before meals, with a little water.
At acute prostatitis appoint 4 tab. 3 times / day. The duration of treatment is 3 Months.
At chronic prostatitis appoint 1 tab. 3-4 times / day. The duration of treatment – 3-6 Months.
At benign prostatic hyperplasia appoint 2 tab. 3 times / day. The duration of treatment is 12 weeks, but it can be increased to 6 Months.
Side effect
With increased individual sensitivity to the drug possible allergic reactions.
Rarely: nausea.
Contraindications
- Hypersensitivity to the drug.
Cautions
In chronic bacterial prostatitis can be used simultaneously with antibacterial drugs (under the supervision of a physician).
Overdose
So far, cases of drug overdose Tsernilton® not observed.
Drug Interactions
Information about drug interactions Tsernilton® with other drugs missing.
Conditions of supply of pharmacies
The drug is resolved to application as an agent Valium holidays.
Conditions and terms
The drug should be stored in a dry, protected from light, inaccessible to children at temperature not exceeding 25 ° C. Shelf life – 5 years. Do not use beyond the expiration date, on the package.
